Type 2 diabetes (T2D) causes microvascular and macrovascular disease^[@b1]^. Diabetic kidney disease is the leading cause of end-stage renal disease worldwide and associated with significant cardiovascular morbidity and mortality^[@b2]^.

The kidney plays an important role in glucose homeostasis. The proximal tubule employs two sodium glucose co-transporters for glucose reabsorption from glomerular filtrate -- SGLT1 and SGLT2. SGLT2 accounts for 90% of glucose reabsorption and is markedly upregulated in T2D. This, along with other renal and extra renal mechanisms, contributes to the persistent hyperglycaemia seen in T2D, making SGLT2 a pragmatic drug target^[@b3]^.

SGLT2 inhibitors (empaglifozin, canaglifozin, dapaglifozin) are approved for treatment of T2D. Improved glycaemic control is achieved by reducing renal glucose reabsorption with a resultant increase in urinary glucose excretion^[@b3]^. The US FDA has mandates that new oral T2D medications undergo clinical trials to assess cardiovascular safety^[@b4]^. The EMPAREG OUTCOME trial demonstrated the cardiovascular benefits of empaglifozin (versus placebo) in patients with T2D with established cardiovascular disease^[@b5]^.

SGLT2 inhibitors may have other benefits including weight loss, lower blood pressure, reduced levels of serum uric acid, improved lipid profiles, lower plasma volume and decreased albuminuria^[@b3]^. The EMPA-REG OUTCOME trial also reported long-term renal effects of empaglifozin in patients with T2D and established cardiovascular risk. Patients who received empaglifozin, in addition to standard care, had a significantly lower risk of progression to macroalbuminuria, doubling of the serum creatinine level and initiation of dialysis compared to placebo, although renal death and incidental microalbumunuria were not affected^[@b4]^.

The renoprotective effects of SGLT2 inhibitors are attributed to their ability to reduce renal hyperfiltration, by vasoconstriction of the afferent arteriole resulting in reduced intraglomerular pressure^[@b5]^. The renal benefits seen in the EMPA-REG OUTCOME trial may be due to the combined reduction in intraglomerular pressures as a result of SGLT2 mediated vasoconstriction of the afferent arteriole and RAAS drugs vasodilating the efferent arteriole^[@b4]^. A subsequent trial, CANVAS-R has demonstrated the renal benefits of canaglifozin over placebo in patients with T2D and heart disease, albeit with an increased risk of amputation^[@b6]^.

SGLT2 inhibitors have been shown to be safe. Genital and urinary infections are the most frequently reported adverse effects, associated with the increased urinary excretion of glucose^[@b3]^. SGLT2 inhibitors are not associated with significant hypoglycaemia^[@b7]^. Some cases of euglycaemic diabetic ketoacidosis have been reported, but this is less of a concern in T2D^[@b3]^. Nephrologists are studying whether SGLT2 inhibitors can slow progression of chronic kidney disease while cardiologists are interested in these drugs to improve heart failure outcomes. SGLT2 inhibitors may be a useful treatment of diverse medical conditions.
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